Document is current

Article History

Accepted: 6 July 2023

First Online: 14 August 2023

Competing interests

: K.B.K. received research grants from Philips Research North America and Google; speaker honorarium from Nikkiso Critical Care Medical Supplies (Shanghai) Co., Ltd; Funding from National Institute of Diabetes and Digestive and Kidney Diseases grant (R01DK131586); also reports consulting fees to Mayo Clinic from Baxter Inc. L.A. holds grant funding from the UCSD-UAB O’Brien Center for AKI (NIDDK) and Sony Electronics, Inc. S.M.B. is supported by a Canada Research Chair in Critical Care Outcomes and Systems Evaluation, and received fees for scientific advisory and speaking from Baxter, fees for scientific advisory from Novartis, fees for data safety monitoring for I-SPY-COVID, and fees for scientific advisory and adjudication from BioPorto. E.F.B. received consulting fees for FAST Biomedical, Wolters-Kluwer (unrelated), and also research support from NIH, AHRQ. R.C.-D.G. received consulting fees from Medtronic for developing CRRT educational material and a speaker honorarium from Nova Biomedical. B.J.E. did not disclose any conflicting interests. L.G.F. received research funding from Baxter, Ortho Clinical Diagnostics, NIHR. E.G. is employed in Philips Research North America and owns stock in Philips. S.L.K.-G. receives royalties from Vigilanz Corporation (Minneapolis, MN, USA) for the Nephrotoxic Injury Negated by Just-in-Time (NINJA) application licensed to Vigilanz from Cincinnati Children’s Hospital Medical Center. S.L.K.-G. receives research funding from NIDDK and NCCIH and is a member of the executive committee for the Society of Critical Care Medicine. J.L.K. received research funding from NIH, Fresenius Medical, Astute/BioMérieux; consulting fees from Baxter, Astute/BioMérieux, Novartis, Guard Therapeutic, and honoraria from ASN. M.L. received research funding from NIDDK (R01DK116986), NSF (2014554) and NCATS (UL1TR002366). R.M. received research funding from the National Institute of Diabetes and Digestive and Kidney Diseases grant (R01DK131586), consulting fees from Baxter Inc unrelated to this study. G.N.N. received consulting fees from AstraZeneca, Reata, BioVie, Daiichi Sankyo, Qiming Capital and GLG, financial compensation as a scientific board member and adviser to Renalytix, and owns equity in Renalytix, Nexus iConnect, Data2Wisdom, and Pensieve Health as a cofounder. J.A.N. received consulting fees form Baxter, Outset, Vifor and Leadiant Biosciences, and research funding from NIDDK (R56 DK126930, R01 DK128208, U01 DK129989, and P30 DK079337). M.O. receives research funding from Fresenius Medical Care, Baxter, Biomérieux and LaJolla Pharma, and speaker honoraria from Fresenius Medical Care, Baxter, BioMérieux and Gilead. P.R. receives research funding from the National Institutes of Health (R21 AG073769, R01 GM110240, OT2 OD032701), NIH/National Institute of Biomedical Imaging and Bioengineering (R01 EB029699), NIH/National Institute of Neurological Disorders and Stroke (R01 NS120924), NIH/National Institute of Diabetes and Digestive and Kidney Diseases (R01 KD121730), and the National Science Foundation (CAREER 1750192). N.M.S. received research funding from the NIHR HS&DR Programme (NIHR131948, co-applicant), NIHR Health Technology Assessment (HTA) program (NIHR129617 Co-Chief Investigator) and speaker honoraria from GE, Fresenius and AstraZeneca, and has a provisional patent for measuring pressure waves in dialysis lines to derive continuous arterial blood pressure. K.S. receives grant funding from Blue Cross Blue Shield of Michigan and Teva Pharmaceuticals for unrelated work, and serves on a scientific advisory board for Flatiron Health (New York, NY, USA). R.L.M. receives consulting fees from Baxter, AM Pharma, BioMérieux, Mallinckrodt, GE Healthcare; Sanofi, Nova BioMed, Abiomed, Novartis, Fresenius, Renasym, Alexion, Renibus, SeaStar, Abbott, Guard. J.K., J.N., N.P., C.R., M.H.R., B.S., D.E.S., S.M.S. and A.B. declare no competing interests.

Free to read: This content has been made available to all.